ZA978865B - Reshaped human anti-HM 1.24 antibody. - Google Patents
Reshaped human anti-HM 1.24 antibody.Info
- Publication number
- ZA978865B ZA978865B ZA9708865A ZA978865A ZA978865B ZA 978865 B ZA978865 B ZA 978865B ZA 9708865 A ZA9708865 A ZA 9708865A ZA 978865 A ZA978865 A ZA 978865A ZA 978865 B ZA978865 B ZA 978865B
- Authority
- ZA
- South Africa
- Prior art keywords
- chain
- antibody
- human
- reshaped human
- region
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP26475696 | 1996-10-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA978865B true ZA978865B (en) | 1998-04-20 |
Family
ID=17407753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9708865A ZA978865B (en) | 1996-10-04 | 1997-10-03 | Reshaped human anti-HM 1.24 antibody. |
Country Status (20)
Country | Link |
---|---|
US (2) | US6699974B2 (sk) |
EP (1) | EP0960936B1 (sk) |
KR (1) | KR100388256B1 (sk) |
CN (2) | CN1765928A (sk) |
AT (1) | ATE512224T1 (sk) |
AU (1) | AU715156B2 (sk) |
BR (1) | BR9712488A (sk) |
CA (1) | CA2267072C (sk) |
CZ (1) | CZ296790B6 (sk) |
HK (1) | HK1024261A1 (sk) |
IL (1) | IL129286A0 (sk) |
NO (1) | NO325178B1 (sk) |
PL (1) | PL187642B1 (sk) |
RU (1) | RU2184147C2 (sk) |
SK (1) | SK44399A3 (sk) |
TR (1) | TR199900722T2 (sk) |
TW (1) | TW530064B (sk) |
UA (1) | UA76934C2 (sk) |
WO (1) | WO1998014580A1 (sk) |
ZA (1) | ZA978865B (sk) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR199901949T2 (xx) | 1997-02-12 | 2000-01-21 | Chugai Seiyaku Kabushiki Kaisha. | Lemfositik t�m�rler i�in �areler. |
AU718463B2 (en) * | 1997-02-28 | 2000-04-13 | Chugai Seiyaku Kabushiki Kaisha | Inhibitor of lymphocyte activation |
CA2308007C (en) | 1997-10-14 | 2011-05-17 | Chugai Seiyaku Kabushiki Kaisha | Enhancer for antibody to lymphocytic tumors |
EP1757941B1 (en) * | 1998-02-25 | 2010-03-31 | Chugai Seiyaku Kabushiki Kaisha | Method for immunochemically assaying anti-hm1.24 antibody |
CA2343054C (en) | 1998-09-18 | 2007-10-30 | Chugai Seiyaku Kabushiki Kaisha | Method for detection or measurement of plasmacytoma cells |
KR20020013538A (ko) | 1999-05-10 | 2002-02-20 | 나가야마 오사무 | 세포의 배양방법 |
CA2382587A1 (en) | 1999-08-23 | 2001-03-01 | Chugai Seiyaku Kabushiki Kaisha | Hm1.24 antigen expression potentiators |
AU2001246846A1 (en) * | 2000-04-06 | 2001-10-23 | Chugai Seiyaku Kabushiki Kaisha | Immunoassay of anti-hm1.24 antibody |
ES2477996T3 (es) | 2000-08-11 | 2014-07-18 | Chugai Seiyaku Kabushiki Kaisha | Preparaciones estabilizadas que contienen un anticuerpo |
WO2002057316A1 (fr) * | 2000-12-28 | 2002-07-25 | Kirin Beer Kabushiki Kaisha | Nouvel anticorps monoclonal |
US7931897B2 (en) | 2001-02-07 | 2011-04-26 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agent for hematopoietic tumors |
EP3088412B1 (en) | 2001-03-09 | 2021-05-05 | Chugai Seiyaku Kabushiki Kaisha | Protein purification method |
WO2002076499A2 (en) * | 2001-03-23 | 2002-10-03 | Aphton Corporation | Combination treatment of pancreatic cancer |
EP1378752A4 (en) * | 2001-04-13 | 2004-08-04 | Chugai Pharmaceutical Co Ltd | METHOD FOR QUANTIFYING ANTIGEN EXPRESSION |
US20090191232A1 (en) * | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
CA2451493C (en) * | 2001-06-22 | 2016-08-23 | Chugai Seiyaku Kabushiki Kaisha | Cell growth inhibitors containing anti-glypican 3 antibody |
CN1525868A (zh) * | 2001-07-09 | 2004-09-01 | 埃弗顿有限公司 | 治疗和预防肝脏、肺脏和食道的癌症和癌症前期症状 |
US20050118163A1 (en) | 2002-02-14 | 2005-06-02 | Hidefumi Mizushima | Antibody-containing solution pharmaceuticals |
US20080219974A1 (en) * | 2002-03-01 | 2008-09-11 | Bernett Matthew J | Optimized antibodies that target hm1.24 |
EP1513879B1 (en) * | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
US20060058511A1 (en) | 2002-08-27 | 2006-03-16 | Chugai Seiyaku Kabushiki Kaisha | Method for stabilizing protein solution preparation |
ES2626268T3 (es) * | 2002-09-11 | 2017-07-24 | Chugai Seiyaku Kabushiki Kaisha | Método de purificación de proteínas |
AU2004225437B2 (en) * | 2003-03-28 | 2010-05-13 | Cancer Advances, Inc. | Gastrin hormone immunoassays |
WO2005014651A1 (ja) | 2003-08-11 | 2005-02-17 | Chugai Seiyaku Kabushiki Kaisha | 糖鎖改変抗hm1.24抗体 |
KR20060069825A (ko) * | 2003-08-01 | 2006-06-22 | 제넨테크, 인크. | 제한된 다양성을 갖는 항체 cdr 폴리펩티드 서열 |
WO2005034994A1 (ja) * | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 固形腫瘍治療剤 |
WO2005044859A2 (en) * | 2003-11-05 | 2005-05-19 | Glycart Biotechnology Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
EP2168986A3 (en) * | 2004-02-19 | 2010-07-28 | Genentech, Inc. | CDR-repaired antibodies |
AU2005228897B2 (en) * | 2004-03-29 | 2009-12-10 | Cancer Advances, Inc. | Monoclonal antibodies to gastrin hormone |
EP2567974A3 (en) * | 2004-09-22 | 2013-05-22 | Cancer Advances, Inc., | Monoclonal antibodies to progastrin |
BRPI0615397B1 (pt) * | 2005-08-26 | 2023-10-03 | Roche Glycart Ag | Anticorpo anti-cd20, composição farmacêutica que o contém e uso do mesmo |
AU2012216702B2 (en) * | 2005-08-26 | 2014-12-04 | Roche Glycart Ag | Modified antigen binding molecules with altered cell signaling activity |
EP2465870A1 (en) | 2005-11-07 | 2012-06-20 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
US20070237764A1 (en) * | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
US9084777B2 (en) | 2005-12-28 | 2015-07-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing formulations |
CA2660795C (en) * | 2006-09-18 | 2014-11-18 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
WO2011028683A1 (en) | 2009-09-03 | 2011-03-10 | Schering Corporation | Anti-gitr antibodies |
TWI609698B (zh) | 2010-01-20 | 2018-01-01 | Chugai Pharmaceutical Co Ltd | 穩定化的含抗體溶液製劑 |
WO2013012022A1 (ja) | 2011-07-19 | 2013-01-24 | 中外製薬株式会社 | アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 |
EP3235557A1 (en) | 2011-09-01 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration |
BR112016014824A2 (pt) | 2013-12-27 | 2017-09-19 | Chugai Pharmaceutical Co Ltd | Método para purificar anticorpo que tem ponto isoelétrico baixo |
EP4056993A1 (en) | 2014-08-20 | 2022-09-14 | Chugai Seiyaku Kabushiki Kaisha | Method for measuring viscosity of protein solution |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
US11583576B2 (en) | 2017-06-15 | 2023-02-21 | Cancer Advances Inc. | Compositions and methods for inducing humoral and cellular immunities against tumors and cancer |
CN109748964B (zh) * | 2017-11-01 | 2020-11-17 | 深圳宾德生物技术有限公司 | CD317单链抗体317scFv、其编码序列及制备方法和应用 |
AU2019247511A1 (en) | 2018-04-06 | 2020-10-22 | Atyr Pharma, Inc. | Compositions and methods comprising anti-NRP2 antibodies |
CN112512480A (zh) | 2018-05-21 | 2021-03-16 | 中外制药株式会社 | 被封入玻璃容器的冷冻干燥制剂 |
US11708186B2 (en) | 2018-05-28 | 2023-07-25 | Chugai Seiyaku Kabushiki Kaisha | Filling nozzle |
CA3156803A1 (en) | 2019-10-03 | 2021-04-08 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2 antibodies |
JPWO2023058723A1 (sk) | 2021-10-08 | 2023-04-13 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO873164L (no) * | 1986-07-30 | 1988-02-01 | Teijin Ltd | Muse-humane kimaere antistoffer. |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
AU668349B2 (en) | 1991-04-25 | 1996-05-02 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
ATE306930T1 (de) * | 1994-08-12 | 2005-11-15 | Immunomedics Inc | Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper |
TR199901949T2 (xx) * | 1997-02-12 | 2000-01-21 | Chugai Seiyaku Kabushiki Kaisha. | Lemfositik t�m�rler i�in �areler. |
US20020034507A1 (en) * | 1997-02-28 | 2002-03-21 | Yasuo Koishihara | Inhibitor of lymphocyte activation |
US7052873B2 (en) * | 1997-10-03 | 2006-05-30 | Chugai Seiyaku Kabushiki Kaisha | Natural human antibody |
CA2308007C (en) * | 1997-10-14 | 2011-05-17 | Chugai Seiyaku Kabushiki Kaisha | Enhancer for antibody to lymphocytic tumors |
DE60305919T2 (de) * | 2002-06-28 | 2007-01-18 | Domantis Limited, Cambridge | Dual-specifische liganden mit erhöhter halbwertszeit |
-
1997
- 1997-03-10 UA UA99042469A patent/UA76934C2/uk unknown
- 1997-10-03 TR TR1999/00722T patent/TR199900722T2/xx unknown
- 1997-10-03 TW TW086114474A patent/TW530064B/zh not_active IP Right Cessation
- 1997-10-03 CN CNA2005100687876A patent/CN1765928A/zh active Pending
- 1997-10-03 IL IL12928697A patent/IL129286A0/xx not_active IP Right Cessation
- 1997-10-03 AT AT97942246T patent/ATE512224T1/de not_active IP Right Cessation
- 1997-10-03 CA CA002267072A patent/CA2267072C/en not_active Expired - Fee Related
- 1997-10-03 CZ CZ0117399A patent/CZ296790B6/cs not_active IP Right Cessation
- 1997-10-03 BR BR9712488-5A patent/BR9712488A/pt not_active Application Discontinuation
- 1997-10-03 ZA ZA9708865A patent/ZA978865B/xx unknown
- 1997-10-03 WO PCT/JP1997/003553 patent/WO1998014580A1/ja active IP Right Grant
- 1997-10-03 KR KR10-1999-7002902A patent/KR100388256B1/ko not_active IP Right Cessation
- 1997-10-03 SK SK443-99A patent/SK44399A3/sk unknown
- 1997-10-03 AU AU43992/97A patent/AU715156B2/en not_active Ceased
- 1997-10-03 PL PL97332742A patent/PL187642B1/pl not_active IP Right Cessation
- 1997-10-03 EP EP97942246A patent/EP0960936B1/en not_active Expired - Lifetime
- 1997-10-03 CN CNB971992150A patent/CN1271205C/zh not_active Expired - Fee Related
- 1997-10-03 RU RU99109034/13A patent/RU2184147C2/ru not_active IP Right Cessation
- 1997-10-03 US US09/269,921 patent/US6699974B2/en not_active Expired - Lifetime
-
1999
- 1999-03-31 NO NO19991591A patent/NO325178B1/no unknown
-
2000
- 2000-03-23 HK HK00101791A patent/HK1024261A1/xx not_active IP Right Cessation
-
2002
- 2002-08-13 US US10/218,253 patent/US7892543B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO1998014580A1 (fr) | 1998-04-09 |
US20030045691A1 (en) | 2003-03-06 |
RU2184147C2 (ru) | 2002-06-27 |
KR100388256B1 (ko) | 2003-06-19 |
CA2267072A1 (en) | 1998-04-09 |
CZ296790B6 (cs) | 2006-06-14 |
HK1024261A1 (en) | 2000-10-05 |
EP0960936A4 (en) | 2005-01-19 |
US6699974B2 (en) | 2004-03-02 |
TR199900722T2 (xx) | 1999-12-21 |
NO991591L (no) | 1999-06-01 |
NO991591D0 (no) | 1999-03-31 |
CA2267072C (en) | 2004-11-30 |
US7892543B2 (en) | 2011-02-22 |
KR20000048884A (ko) | 2000-07-25 |
CZ117399A3 (cs) | 1999-09-15 |
AU4399297A (en) | 1998-04-24 |
AU715156B2 (en) | 2000-01-20 |
EP0960936A1 (en) | 1999-12-01 |
PL187642B1 (pl) | 2004-08-31 |
CN1765928A (zh) | 2006-05-03 |
SK44399A3 (en) | 2000-05-16 |
PL332742A1 (en) | 1999-10-11 |
CN1235639A (zh) | 1999-11-17 |
TW530064B (en) | 2003-05-01 |
CN1271205C (zh) | 2006-08-23 |
ATE512224T1 (de) | 2011-06-15 |
US20030129185A1 (en) | 2003-07-10 |
UA76934C2 (en) | 2006-10-16 |
BR9712488A (pt) | 1999-10-19 |
IL129286A0 (en) | 2000-02-17 |
NO325178B1 (no) | 2008-02-11 |
EP0960936B1 (en) | 2011-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA978865B (en) | Reshaped human anti-HM 1.24 antibody. | |
AU2936395A (en) | Reconstituted human antibody against human interleukin-8 | |
IL138801A0 (en) | Humanized antibody against human tissue factor and process for the preparation thereof | |
EP1020522A4 (en) | NATURAL HUMAN ANTIBODY | |
IL189629A0 (en) | Compositions containing human ctla-4 antibodies | |
EP0536275A4 (en) | Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof | |
FI861150A (fi) | Monoklonala antikroppar mot metallkelat. | |
LU91271I2 (fr) | Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI) | |
NL300433I1 (en) | Methods and compositions for the treatment of glomerulonephritis | |
BG101966A (en) | Application of 1l-agonist for the treatment of lack of urine retention | |
CY2583B2 (en) | Reshaped monoclonal antibodies against an immunoglobulin isotype | |
WO1991010735A3 (fr) | Recepteur humain de la tsh. sequence codant pour ce recepteur | |
AU4441393A (en) | Granulocyte-binding antibody fragments, their preparation and use | |
RU93035807A (ru) | Способ лечения юношеского эпифизиолиса |